There are 1105 resources available
196P - Perioperative FLOT + immunotherapy for resectable gastric and gastroesophageal junction cancer: A systematic review and meta-analysis
Presenter: Lorenz Fort Revillas
Session: Poster Display session
Resources:
Abstract
197P - Efficacy and safety of lenvatinib plus adebrelimab combined with hepatic arterial infusion chemotherapy (HAIC) for unresectable biliary tract cancer
Presenter: Wenbo Guo
Session: Poster Display session
Resources:
Abstract
198P - The Efficacy and safety of adjuvant nivolumab therapy after neoadjuvant docetaxel plus cisplatin, 5-FU therapy for resectable locally advanced esophageal squamous cell carcinoma
Presenter: Nozomu Ogura
Session: Poster Display session
Resources:
Abstract
199P - Impact of baseline tumour burden on outcomes in EMERALD-1: A phase III study of durvalumab (D) ± bevacizumab (B) with transarterial chemoembolisation (TACE) in embolisation-eligible unresectable hepatocellular carcinoma (uHCC)
Presenter: Masatoshi Kudo
Session: Poster Display session
Resources:
Abstract
200P - Final analysis of the ELIXIR study: A prospective, multicenter, observational study to evaluate the efficacy and safety of atezolizumab + bevacizumab (Atezo+Bev) in Japanese patients with unresectable hepatocellular carcinoma (uHCC) in a real-world clinical setting
Presenter: Tetsuo Takehara
Session: Poster Display session
Resources:
Abstract
201P - Perioperative pembrolizumab and lenvatinib for resectable hepatocellular carcinoma: Updated efficacy and safety results from the phase II NeoLEAP-HCC study
Presenter: Huichuan Sun
Session: Poster Display session
Resources:
Abstract
202P - Hepatic arterial infusion tislelizumab and chemotherapy plus DEB-TACE in combination with lenvatinib for first-line treatment of unresectable HCC: A prospective, single arm, phase II study (HAITC study)
Presenter: HAIPENG Yu
Session: Poster Display session
Resources:
Abstract
203P - Epigenetic promoter signatures and ectopic gain of distal intergenic gene regulators contribute to hepatocarcinogenesis: The Planet study
Presenter: Hong-Yi Lin
Session: Poster Display session
Resources:
Abstract
205P - Transarterial chemoembolization with immune checkpoint inhibitors and anti-VEGF antibody/tyrosine kinase inhibitors as first-line treatment for intermediate-stage hepatocellular carcinoma (CHANCE2202): A target trial emulation study
Presenter: Jian-Jian Chen
Session: Poster Display session
Resources:
Abstract
206P - Avatrombopag for the treatment of immune checkpoint inhibitor/targeted therapy-related thrombocytopenia in patients with hepatocellular carcinoma: A prospective, multicenter, single-arm trial
Presenter: Yong-Shuai Wang
Session: Poster Display session
Resources:
Abstract